Evaluation of Costs Associated with Tolvaptan-Mediated Hospital Length of Stay Reduction Among US Patients with the Syndrome of Inappropriate Antidiuretic Hormone Secretion, Based on SALT-1 and SALT-2 Trials

Anderson RJ, 1985, Ann Intern Med., 102, 164, 10.7326/0003-4819-102-2-164

Baran D, 1984, Clin Nephrol., 22, 72

Boscoe A, 2006, Cost Eff Resour Alloc., 4, 10, 10.1186/1478-7547-4-10

Esposito P, 2011, Nephron Clin Pract., 119, c62, 10.1159/000324653

Shapiro DS, 2010, Intern Med J., 40, 574, 10.1111/j.1445-5994.2010.02217.x

Hannon MJ, 2010, Eur J Endocrinol., 162, S5, 10.1530/EJE-09-1063

Nielsen S, 2002, Physiol Rev., 82, 205, 10.1152/physrev.00024.2001

Ball SG, 2007, Ann Clin Biochem., 44, 417, 10.1258/000456307781646030

Verbalis JG, 2010, Endocrinol Nutr., 57, 30, 10.1016/S1575-0922(10)70020-6

Sherlock M, 2010, Eur J Endocrinol., 162, S13, 10.1530/EJE-09-1057

Schrier RW, 2006, N Engl J Med., 355, 2099, 10.1056/NEJMoa065181

Verbalis JG, 2011, Eur J Endocrinol., 164, 725, 10.1530/EJE-10-1078

HCUP Nationwide Inpatient Sample (NIS)., Healthcare Cost and Utilization Project (HCUP). 2007–2009

Welcome to HCUPnet., Healthcare Cost and Utilization Project (HCUP)

Fenske W, 2010, Horm Metab Res., 42, 691, 10.1055/s-0030-1255117